Market Cap 52.59M
Revenue (ttm) 37.87M
Net Income (ttm) -6.48M
EPS (ttm) N/A
PE Ratio 37.33
Forward PE N/A
Profit Margin -17.11%
Debt to Equity Ratio 0.18
Volume 46,100
Avg Vol 81,332
Day's Range N/A - N/A
Shares Out 14.96M
Stochastic %K 43%
Beta -0.39
Analysts Strong Buy
Price Target $8.50

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 615 255 0068
Fax: 615 255 0094
Address:
1600 West End Avenue, Suite 1300, Nashville, United States
ripztrip
ripztrip Jul. 29 at 2:39 AM
1 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Jul. 28 at 9:38 PM
$CAPR $CPIX $SRPT 🎯 CAPR should do well in reaction to this news. Perfect timing for capr for their discussions with fda.
0 · Reply
CpixPumper
CpixPumper Jul. 28 at 9:35 PM
$CAPR $CPIX $SRPT The decision to unhalt SRPT's drug after only such a short pause is likely to come from the top, big guns like Makary & Kennedy, It proves that Makary & Kennedy recognize there is an urgent need to DMD patients due to highly unmet need. This is a super-bullish sign for ALL DMD drugs, speed approvals and Accelerated Approvals should be much more easier than before. This new FDA (Makary) means what they said about speedy approvals for rare disease.
0 · Reply
YoloAlfred
YoloAlfred Jul. 28 at 2:47 PM
$CPIX Still a STRONG BUY 7/25/2025
0 · Reply
CpixPumper
CpixPumper Jul. 28 at 12:38 PM
$CPIX @haha1978 Here is some correct info for you: 1) They should have 41 patients in OLE Trial if no dropouts. because all patients (including placebo and low dose) will join OLE high-dosed. 2) OLE is open-label, so there is no "unblinding". They know the result along the way during the trial. Management said their 3-year OLE has finished last month, and they are preparing the data to report to FDA.
2 · Reply
haha1978
haha1978 Jul. 28 at 4:24 AM
$CPIX yes im aware but the days of p2 studies are over after the bs Peter Marks did. If its like this in CBER it will be on the other as well. Its the FDA and will be consistent imo. I hope cpix gets that AA on the 3 year Ole but capr didnt and after srpt killing another kid Friday News the fda is going to take things more seriously. I doubt ifetroban will cause a death. Let's see if a 3 year study of 12 patients on high dose will be sufficient. Hopefully they unblinded early and put half the placebo on it for 25 each year last 2 years then they have a better shot at AA.
0 · Reply
CpixPumper
CpixPumper Jul. 28 at 2:27 AM
$CAPR $CPIX There are 2 main departments under FDA: CBDR : led by Dr. Prasad. (Cell & Gene) CDER: led by Dr. George Tidmarsh (chemical based drugs) So, relax, Prasad does not "rule" all the drugs. Majority of drugs are under CDER (Dr. Tidmarsh ) Here is from article below:
0 · Reply
CpixPumper
CpixPumper Jul. 28 at 1:28 AM
$CPIX $CAPR Come on ! Haha1978 :-) As a CPIX investor, you should at least know that CPIX's drug is NOT cell or gene therapy !!! :-) CPIX's drug is traditional (chemical-based) drug so it does NOT belong to CBER (headed by Prasad) (Thank god :-). CPIX's drug belong to CDER, which is led by :
0 · Reply
haha1978
haha1978 Jul. 28 at 12:56 AM
$CPIX raising the bar for DMD. P3 are required imo. Peter Marks days of p2 approval are over.
0 · Reply
jiggs10
jiggs10 Jul. 26 at 3:32 PM
$CPIX Nice posts Red Hole
0 · Reply
Latest News on CPIX
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 18, 2025, 7:30 AM EST - 5 months ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA


FDA APPROVES ACETADOTE® sNDA

Dec 9, 2024, 4:05 PM EST - 8 months ago

FDA APPROVES ACETADOTE® sNDA


Cumberland Pharmaceuticals Reports 41% Revenue Growth

Nov 8, 2022, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports 41% Revenue Growth


ripztrip
ripztrip Jul. 29 at 2:39 AM
1 · Reply
TheGodsMustBeCrazy
TheGodsMustBeCrazy Jul. 28 at 9:38 PM
$CAPR $CPIX $SRPT 🎯 CAPR should do well in reaction to this news. Perfect timing for capr for their discussions with fda.
0 · Reply
CpixPumper
CpixPumper Jul. 28 at 9:35 PM
$CAPR $CPIX $SRPT The decision to unhalt SRPT's drug after only such a short pause is likely to come from the top, big guns like Makary & Kennedy, It proves that Makary & Kennedy recognize there is an urgent need to DMD patients due to highly unmet need. This is a super-bullish sign for ALL DMD drugs, speed approvals and Accelerated Approvals should be much more easier than before. This new FDA (Makary) means what they said about speedy approvals for rare disease.
0 · Reply
YoloAlfred
YoloAlfred Jul. 28 at 2:47 PM
$CPIX Still a STRONG BUY 7/25/2025
0 · Reply
CpixPumper
CpixPumper Jul. 28 at 12:38 PM
$CPIX @haha1978 Here is some correct info for you: 1) They should have 41 patients in OLE Trial if no dropouts. because all patients (including placebo and low dose) will join OLE high-dosed. 2) OLE is open-label, so there is no "unblinding". They know the result along the way during the trial. Management said their 3-year OLE has finished last month, and they are preparing the data to report to FDA.
2 · Reply
haha1978
haha1978 Jul. 28 at 4:24 AM
$CPIX yes im aware but the days of p2 studies are over after the bs Peter Marks did. If its like this in CBER it will be on the other as well. Its the FDA and will be consistent imo. I hope cpix gets that AA on the 3 year Ole but capr didnt and after srpt killing another kid Friday News the fda is going to take things more seriously. I doubt ifetroban will cause a death. Let's see if a 3 year study of 12 patients on high dose will be sufficient. Hopefully they unblinded early and put half the placebo on it for 25 each year last 2 years then they have a better shot at AA.
0 · Reply
CpixPumper
CpixPumper Jul. 28 at 2:27 AM
$CAPR $CPIX There are 2 main departments under FDA: CBDR : led by Dr. Prasad. (Cell & Gene) CDER: led by Dr. George Tidmarsh (chemical based drugs) So, relax, Prasad does not "rule" all the drugs. Majority of drugs are under CDER (Dr. Tidmarsh ) Here is from article below:
0 · Reply
CpixPumper
CpixPumper Jul. 28 at 1:28 AM
$CPIX $CAPR Come on ! Haha1978 :-) As a CPIX investor, you should at least know that CPIX's drug is NOT cell or gene therapy !!! :-) CPIX's drug is traditional (chemical-based) drug so it does NOT belong to CBER (headed by Prasad) (Thank god :-). CPIX's drug belong to CDER, which is led by :
0 · Reply
haha1978
haha1978 Jul. 28 at 12:56 AM
$CPIX raising the bar for DMD. P3 are required imo. Peter Marks days of p2 approval are over.
0 · Reply
jiggs10
jiggs10 Jul. 26 at 3:32 PM
$CPIX Nice posts Red Hole
0 · Reply
YoloAlfred
YoloAlfred Jul. 25 at 8:24 PM
$CPIX Same...any big news .....and BOOM....Tiny amount of shares Market Maker has .
0 · Reply
peapope
peapope Jul. 25 at 8:20 PM
$CPIX Bids firming up some good institutions own I am long thru earnings glta
0 · Reply
CpixPumper
CpixPumper Jul. 25 at 4:38 PM
$CPIX A drug cannot be considered as a solution of a highly unmet treatment need like DMD Cardiomyopathy if it is too expensive for every patient to afford. Most of the patients will still suffer because they cannot afford the treatment. CPIX's drug should be very affordable to all patient because it is very low cost to manufacture the drug. and it can be manufactured in large quantity in short time. FDA knows that fact.
0 · Reply
CpixPumper
CpixPumper Jul. 25 at 4:21 PM
$CPIX Why did FDA select CPIX's drug for Orphan Drug Program Funding among 100+ applicants ??? Because CPIX's drug has shown it can significantly improve the severe DMD mice survival rate, also, CPIX's drug will be a practical treatment for ALL DMD patients because it will be very affordable compared to Cell treatments. There is no need for expensive travel or hospital stay for DMD patients because it is an oral pill taken at home. Now, that CPIX's phase 2 data has shown promising result in both LVEF and NT-proBNP, Accelerated Approval is the pathway to make this drug available to the DMD patients ASAP.
0 · Reply
YoloAlfred
YoloAlfred Jul. 25 at 2:28 PM
$CPIX in your opinion do we check all the marks for a potential FAST TRACK?
1 · Reply
YoloAlfred
YoloAlfred Jul. 25 at 1:41 PM
$CPIX added more....now 4,023 shares
0 · Reply
CpixPumper
CpixPumper Jul. 25 at 12:56 PM
$CPIX Survival Rate is the only endpoint that FDA wants to see in DMD Cardio trials, but it is not practical because DMD patients can live for decades. So, FDA uses surrogate endpoints to predict the future survival rate. the recommended endpoints are LVEF and NT-proBNP biomarker. The fact that CPIX's drug has shown to improve the survival rate from 43% (untreated DMD mice) to 100% (treated DMD mice) has helped CPIX to win the FDA's funding for their Phase 2 DMD Trial. This data will give great support to their upcoming FDA review: FDA wants to see survival rate.
0 · Reply
YoloAlfred
YoloAlfred Jul. 25 at 11:51 AM
$CPIX adding more
0 · Reply
YoloAlfred
YoloAlfred Jul. 25 at 11:04 AM
$CPIX another setback for ELEVIDYS
0 · Reply
YoloAlfred
YoloAlfred Jul. 24 at 6:17 PM
$CPIX 3,922 shares now....around $13K bet
0 · Reply
YoloAlfred
YoloAlfred Jul. 24 at 4:15 PM
$CPIX It's only fair I tell you guys about my largest position $ESPR
2 · Reply
YoloAlfred
YoloAlfred Jul. 24 at 2:50 PM
$CPIX 🤔🤔🤔🤔$1.7 Billion with a 15 million shares outstanding 🤔🤔🤔🤑🤑thats just Ifetroban if passed by FDA
0 · Reply